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Aims Tissue-type plasminogen activator (t-PA) is produced by endothelial cells (EC) and is responsible for the removal of
intravascular fibrin deposits. We investigated whether expression of t-PA by EC is under epigenetic control.
Methods
and results
Methylation analysis of the proximal t-PA promoter revealed a stretch of unmethylated CpG dinucleotides from pos-
ition 2121 to +59, while upstream CpG dinucleotides were all methylated. In contrast, in human primary hepato-
cytes, which express t-PA at much lower levels than EC, the proximal promoter was partially methylated. Treatment
of EC with the non-specific histone deacetylase (HDAC) inhibitors butyrate and trichostatin and with MS275, a
specific inhibitor of class I HDAC, resulted in a time- and dose-dependent increase in t-PA expression. Garcinol
and anacardic acid, inhibitors of the histone acetyl transferases CBP/p300 and PCAF, reduced basal and HDAC
inhibitor-induced t-PA expression, whereas curcumin, an inhibitor of CBP/p300 only, had no effect. We performed
chromosome immunoprecipitation analysis of the t-PA promoter using antibodies specific for acetylated histone H3
or H4 and observed an increase in H3 acetylation of 10+3 and 44+14-fold in EC treated with trichostatin or
MS275, respectively, and in H4 acetylation of 7.7+ 1.4 and 16+ 3-fold, respectively.
Conclusion The proximal t-PA promoter is unmethylated in human EC and partially methylated in human primary hepatocytes.
Expression of t-PA by EC is repressed by HDACs in a mechanism that involves de-acetylation of histone H3 and H4.
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1. Introduction
Activation of the fibrinolytic system is the principal mechanism by
which intravascular fibrin deposits are removed. Tissue-type plasmi-
nogen activator (t-PA) converts plasminogen into the protease
plasmin, which efficiently degrades fibrin into fibrin degradation pro-
ducts. The vascular endothelium is an important source of circulating
t-PA. It releases t-PA in a constitutive manner and in a regulated
manner. In human forearm perfusion studies, acute release of t-PA
was demonstrated in response to 1-desamino-8-arginine-vasopressin1
and in a rat hind limb perfusion system, acute t-PA secretion was
induced by a variety of secretion agonists.2 The storage of tissue-type
plasminogen in the vascular endothelium and its regulated release
after endothelial activation by a variety of secretagogues, such as
thrombin, assures that fibrin deposited in front of an intact endo-
thelium is rapidly removed. Thus, experimental induction of dissemi-
nated intravascular coagulation in chimpanzees or baboons by
injection of a mixture of activated coagulation factor Xa and phospho-
lipids was followed within minutes by a massive (.100-fold) increase
in plasma t-PA concentrations. The amount of t-PA released was suf-
ficient to rapidly restore blood circulation even under conditions
where all fibrinogen had been converted into fibrin.3,4 The rapidity
of the t-PA release response suggested the presence of an endothelial
storage pool for t-PA. Indeed, studies in vitro and in vivo have shown
that t-PA is stored in endothelial cells (EC) in Weibel–Palade
bodies and in distinct small granules, and is released by thrombin, his-
tamine, phorbol ester, and the cAMP-inducing agent forskolin.5–8 Bio-
synthesis and storage of t-PA in EC is increased by a number of factors
such as vascular endothelial growth factor, basic fibroblast growth
factor, thrombin, retinoic acid and forskolin and phorbol ester,
which activate the protein kinase A and the protein kinase C, respect-
ively.8–12 In addition, trichostatin and butyrate, which are non-specific
histone deacetylase (HDAC) inhibitors increase t-PA expression in
EC,8,13 which implies a role for epigenetic control of t-PA gene
expression.
The PA system not only plays an important role in the removal of
incipient fibrin deposits, but also in a variety of important physiological
and pathological conditions such as development, tissue remodelling,
* Corresponding author. Tel: +41 0 22 3795493; fax: +41 0 22 37 29299, Email: egbert.kruithof@hcuge.ch
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2011. For permissions please email: journals.permissions@oup.com.
Cardiovascular Research (2011) 90, 457–463
doi:10.1093/cvr/cvr028
tumour invasion and metastasis, inflammation, neuronal plasticity, and
blood–brain barrier function.
Epigenetic events, as characterized by cell-type specific modifi-
cations in the pattern of DNA methylation and of histone modifi-
cations at the gene promoter are of major importance for
understanding gene regulation. In particular, epigenetics provides a
mechanism by which cells can respond to their environment.
Recent studies illustrate the importance of epigenetics as a link
between the environment and the risk of cardiovascular disease.14–16
Epigenetic events are not only important for cardiovascular disease,
but also for tumour angiogenesis and cancer treatment as revealed
by the potent anti-angiogenic effects of HDAC inhibitors17,18 and
for the understanding of inflammation.19
In view of the many activities of epigenetic drugs on the vascular
system in the context of cardiovascular disease or cancer and in
view of the role of t-PA in dissolution of fibrin deposits and in
many other physiological and pathological situations where the PA
system is involved, it is important to have a better understanding of
the epigenetic aspects of t-PA expression by EC. The aim was to
study epigenetic control of t-PA expression by EC. We focused our
study on the methylation state of the t-PA promoter and on the
role of HDAC and of histone acetyl transferases (HATs) in the regu-
lation of t-PA expression. We observed that inhibition of class I
HDAC led to an increase in t-PA expression by EC, which was
accompanied by an increase in acetylation of histones H3 and H4
associated with the t-PA promoter. Inhibition of the HATs p300/
CBP and PCAF reduced basal t-PA expression and abrogated the
effect of HDAC inhibition. A study of CpG dinucleotide methylation
at the t-PA promoter revealed an unmethylated stretch of DNA from
2121 to +59 in EC, whereas in human hepatocytes, which express
less t-PA, the same t-PA promoter region is partially methylated.
2. Methods
2.1 Reagents
Butyrate and trichostatin were from Sigma Aldrich (Schnelldorf,
Germany). MS275, anacardic acid, curcumin, and garcinol were from
Enzo Life Sciences AG (Lausen, Switzerland).
2.2 Cell culture
Umbilical cords were obtained from the local maternity wardwith informed
consent from the parents and with approval from the hospital Ethics Com-
mittee. The investigation conforms with the principles outlined in the
Declaration of Helsinki. Human umbilical cord-derived endothelial cells
(HUVEC) were isolated as described20 and cultured in EGM-2 medium
(Cambrex, Walkersville, MD, USA). The cells were expanded in EGM-2
medium, containing VEGF, IGF, FGF-B, EGF, ascorbic acid, gentamycin,
and heparin, supplemented with 2% foetal bovine serum. Cells were pas-
saged by trypsin-EDTA (Seromed Biochrom KG, Berlin, Germany) treat-
ment and used at passage 1–3. Stimulation of the cells was done in the
same medium, but without the addition of growth factors. Human
primary hepatocytes were purchased and grown in HCM bulletkit
medium, both from Lonza (Walkersville, MD, USA). HuH7 and HepG2
cells were grown in Dulbecco’s modified Eagle’s medium with 10% foetal
bovine serum (Gibco Invitrogen, Carlsbad, CA, USA).
2.3 Quantitative reverse transcriptase
real-time PCR
Total cellular RNA was isolated using Trizol reagent (Invitrogen) and
reverse transcribed using the Improm-II reverse transcriptase system
from Promega (Madison, WI, USA). Quantitative reverse transcriptase
real-time PCR (qPCR) was performed as described previously21 using
the DDCT method and GAPDH as the control housekeeping gene for
comparison of the effect of agonists on t-PA expression in HUVEC. For
comparison of t-PA mRNA levels between HUVEC and hepatocytes or
hepatoma cells a panel of three control housekeeping genes was used:
18S rRNA, human b2-microglublin and elongation factor 1 alpha
subunit. The oligonucleotide sequences used for qPCR are given in
Table 1.
2.4 Measurement of t-PA antigen
concentrations




The chromosome immunoprecipitation (ChIP) assay was performed
according to the manufacturer’s instructions using the reagents provided
(Upstate Biotechnology, Temacula, CA, USA). HUVEC were treated for
6 h with 3 mM of trichostatin or MS275 or control medium. About 3.106
cells at passage 2 were used per assay. Chromatin was cross-linked to
DNA by adding formaldehyde to the medium to a final concentration of
1% and incubating at 378C during 10 min. After twowashes with cold phos-
phate buffered saline containing proteases inhibitors (PMSF 1 mM, aprotinin
1 mg mL21, and pepstatin 1 mg mL21), cells were scraped and harvested by
a brief centrifugation (4 min 600 g 48C). Cells pellets were resuspended in
SDS lysis buffer containing protease inhibitors (200 mL per 1.106 cells)
and incubated on ice for 10 min. The lysate was sonicated to shear the
DNA to a length between 200 and 1000 bp with cooling on ice between
cycles and then centrifuged for 10 min at 13 000 g at 48C. The supernatant
was diluted 10-fold in ChIP buffer containing protease inhibitors, a 100 mL
aliquot of the diluted supernatant was removed to serve as input sample.
The chromatin solution was pre-cleared by adding 75 mL of a 50% protein
A sepharose slurry containing salmon spermDNAand left on a rocking plat-
form for 30 min at 48C. Chromatin solutions were recovered by 1 min cen-
trifugation at 200 g and 48C and incubated overnight on a rocking platform
with 10 mL of rabbit anti-acetyl histone H3 (1 mg/mL) or anti-acetyl histone
H4 (Upstate Biotechnology) at 48C. ‘Mock’ samples were prepared by incu-
bation of the chromatin solution under the same conditions with 10 mL of
non-relevant rabbit IgG (1 mg/mL). Then 60 mL of a 50% protein A sepha-
rose/ssDNA slurrywas added and incubated on a rocking platform for 1 h at
48C. After centrifugation at 200 g, agarose beads were washed and the
immune complexes extracted twice with 250 mL of elution buffer (SDS
1%, 0.1 M NaHCO3). Then 20 mL of 5 M NaCl was added to the eluate
and the input fractions and the formaldehyde cross-links were reversed
by heating at 658C for 4 h. After treatment by proteinase K, tris–HCl and
EDTA for 1 h at 458C, the DNAwas purified. The recovered DNAwas sus-
pended inH2O and analysed by qPCR using the primers given in Table 1. The
primers amplified a 191 bp DNA fragment corresponding to the region
21037 to 2846 with respect to the transcription initiation site of the
t-PA gene. The ChIP results are expressed in percent of the input fraction.
2.6 DNA methylation analysis
A quantity of 500 ng of extracted DNA was modified with sodium bisul-
fite, which converts all unmethylated cytosines to uracil, whereas methyl-
ated cytosines remain unchanged. Bisulfite conversion and desulfonation
were carried out according to the procedure of the manufacturer (Invitro-
gen). The resulting DNA was amplified by nested PCR using three primer
sets to cover three overlapping regions of the proximal t-PA promoter. In
short, 100 ng of bisufite-treated DNA was subjected to 35 cycles of PCR
amplification in a volume of 50 mL using the outer primers described in
Table 1. Three microlitres of the PCR product were used as template
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for another 35 cycles of nested PCR amplification in a volume of 50 mL
using the inner primers listed in Table 1. After primary and secondary
amplification the PCR products were purified with the High Pure PCR
Product Purification kit (Roche, Basel Switzerland) and sequenced directly
to compare the degree of cytosine methylation.
2.7 Statistics
The significance of differences was determined by Student’s t-test.
3. Results
3.1 DNA methylation state at the t-PA
promoter in HUVEC and in liver-derived
cells and expression of t-PA
We analysed the methylation state of the proximal t-PA promoter in
HUVEC, in human primary hepatocytes, and in two human hepatoma
cell lines, HuH7 and HepG2. The analysis was done by DNA sequen-
cing of bisulfite-treated DNA, which converts unmethylated C’s into
uracil and has no effect on methylated C’s. The t-PA promoter region
was amplified by nested PCR using primers for bisulfite-treated DNA
and then sequenced. The methylation state of a specific CpG dinu-
cleotide residue was determined from the relative peak heights in
the sequence profile and for each CpG dinucleotide position
expressed as % (C/C + T). We observed that in EC the t-PA promo-
ter was almost completely (.95%) methylated at positions 2647,
2618, 2548, 2537, 2452, 2421, and 2366 (95.4%+ 4.3,
average+ SD), while at positions 2121, 2105, 281, 251, +27,
+42, +50, and +59 no methylated CpG dinucleotide was detected
(Figure 1). In comparison, the methylation state of the t-PA promoter
in HuH7 human hepatoma cells was quite different. In the region
2647 to 2366 CpG dinucleotide methylation was significantly
lower than in HUVEC (average: 70.8%+ 13.1) (P, 0.001, paired
t-test), while in the region 2121 to +59 CpG dinucleotide methyl-
ation was significantly higher (average: 61.1%+19.0) (P, 0.0002)
(Figure 1). Intermediate CpG dinucleotide methylation was observed
for human hepatocytes and HepG2 hepatoma cells. Interestingly, in
human hepatocytes CpG dinucleotides 121 and 105 were 80%
methylated, whereas in HUVEC these CpG dinucleotides were fully
unmethylated. Also, in hepatocytes partial methylation was observed
of CpG dinucleotides at 27 and 42, which are located just down-
stream of the transcription initiation site.
We compared t-PA antigen release and t-PA mRNA between
HUVEC and the liver-derived cells. Release of t-PA antigen and
level of t-PA mRNA were 11.9 and 5.5-fold higher, respectively, in
HUVEC than in the primary human hepatocytes (P, 0.01)
(Figure 2). Expression of t-PA in HepG2 and HuH7 hepatoma cells
was 3- and 10-fold lower, respectively, than in hepatocytes (Figure 2).
3.2 Effect of histone deacetylase inhibitors
on t-PA expression by endothelial cells
To investigate whether HDACs are involved in the repression of t-PA
expression in HUVEC, cells were treated with different concen-
trations of sodium butyrate or trichostatin, which are selective for
both class I and class II HDAC. After 24 h we observed for both
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Table 1 Oligonucleotide primers used in this study
Locationa
GAPDH mRNA qPCR Forward GGTGAAGGTCGGAGTCAAC
Reverse CCATGGGTGGAATCATATTG
t-PA mRNA qPCR Forward CCGGCTACGGCAAGCA
Reverse AGCGGCTGGATGGGTACA
18S rRNA qPCR Forward AGTCCCTGCCCTTTGTACACA
Reverse GATCCGAGGGCCTCACTAAAC
hB2M mRNA qPCR Forward TGCTCGCGCTACTCTCTTT
Reverse TCTGCTGGATGACGTGAGTAAAC
EEF1a1 mRNA qPCR Forward AGCAAAAATGACCCACCAATG
Reverse GGCCTGGATGGTTCAGGATA
t-PA (CHIP analysis) Forward GTCGGTCATCCCACAATTTC 21037 to 2846
Reverse CAGGTCACGTGAGGATCAGA
t-PA promoter 1 Outer Forward TTTGAAAAGGTGTTAGTAAG 2705 to 2382
Reverse ACCACTAAAAAAACAAAACC
Inner Forward TAAGGGAAATGGTTTGTTTA 2721 to 2416
Reverse CTACRATAAAAAATACCCCCATA
t-PA promoter 2 Outer Forward TTTGGGTTTATTTAAGGGGATGT 2577 to +156
Reverse AAAAATTTTCTCTCCAACCCTAAAC
Inner Forward GAGGTTATTTATTGTAGTTTTGTATTTTAT 2535 to +118
Reverse CAACTCTAAACTCCCCACAACTC
t-PA promoter 3 Outer Forward TTAGGATTTTAAAGGAAGATGATTTTTAA 2176 to +222
Reverse AAAAAAACAAACCCCAAAATACAA
Inner Forward AAAGGAAGATGATTTTTAAGGTTTTATTT 2166 to +155
Reverse AAAATTTTCTCTCCAACCCTAAACT
aThe gene location is given with respect to the transcription initiation site according to the NCBI Reference Sequences for t-PA: NM_033011.2 and NM_000930.3. Gene abbrevations:
t-PA, tissue-type plasminogen activator; hB2M, human b2 microglobulin; EEF1a1, elongation factor 1 alpha subunit.
qPCR, quantitative reverse transcriptase real-time PCR.
CHIP analysis, chromosome immunoprecipitation analysis.
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inhibitors a dose-dependant increase in t-PA antigen release (Figure 3).
The effect of trichostatin on t-PA mRNA levels was transient, with a
peak at 10 h, whereas the effect of butyrate on t-PA mRNAwas stable
for at least 24 h (Figure 3). To determine which HDAC class was the
target of inhibitors stimulating t-PA expression, HUVEC were treated
with MS275, a selective inhibitor of the Class I HDAC. A time
response curve of the t-PA mRNA in cells treated with 3 mM revealed
a maximal response at 24 h (data not shown). The concentration of
MS275 that gave a half maximal increase in t-PA (EC50) was calcu-
lated using the four parameter model and Prism vs. 5.0 software for
Macintosh. For the effect of MS275 on t-PA antigen release and
t-PA mRNA, the value of EC50 was 1.88+0.31 and 2.01+
0.12 mM, respectively (Figure 4). These values are compatible with
known IC50’s for HDAC1, 2, and 3, but not for HDAC8.
3.3 Effect of HDAC inhibitors on histone
acetylation at the t-PA promoter
HDAC and HAT act not only on histones, but also on a variety of
other proteins that may influence gene regulation. To determine
whether HDAC inhibition had a direct effect on histone acetylation
at the t-PA promoter, we performed chromatin immunoprecipitation
experiments on DNA isolated from HDAC inhibitor-treated EC and
from control EC, by using antibodies directed at acetylated histones
H3 or H4, followed by qPCR using primers specific for the region
21037 to 2846 with respect to the transcription initiation site of
the t-PA gene. Results are expressed as percentage of input DNA.
Immunoprecipitation of t-PA promoter DNA with non-relevant anti-
body, used as negative control, was negligible.
Acetylation of histone H3 and H4 associated with the t-PA promo-
ter region in EC was low in non-treated cells (0.46+0.38 and 1.34+
0.84%, respectively). After treatment with trichostatin or MS275,
10+ 3 (n ¼ 4) and 44+14-fold more t-PA promoter DNA was
associated with acetylated H3 histone, respectively, and 7.7+1.4
Figure 1 DNA methylation status of the t-PA promoter and t-PA mRNA levels in HUVEC and human liver-derived cells. The methylation state of
the t-PA promoter in HUVEC, in human primary hepatocytes or in two human hepatoma cells, HepG2 or HuH7 cells, was determined by direct
sequencing of bisulfite treated, PCR-amplified DNA. Left: Illustration of the approach to determine the CpG dinucleotide methylation state at the
t-PA promoter. The figure shows the DNA sequence profile of bisulfite-treated DNA for to the t-PA promoter region at positions 2125 to
290 with respect to the transcription initiation site. Note that the DNA profile of HuH7 cells shows a majority of C’s (blue) and a minority of
T’s (red) at CpG dinucleotide positions 2121 and 2105 implying that the majority of CpG dinucleotides at this position are methylated. In contrast,
for HUVEC, the DNA profile shows no C’s at positions 2121, and 2105. Bisulfite conversion of C’s outside a CpG dinucleotide context was com-
plete as shown by a comparison of the DNA sequence profiles and the corresponding genomic DNA sequence below, with CpG dinucleotides under-
lined and marked in blue. Right: The degree of CpG dinucleotide methylation in the region 2647 to +94 of the proximal t-PA was estimated by
comparison of the ratio of cytidine and thymidine peak heights at each CpG dinucleotide position, as illustrated at the figure at the left. Note the
absence of DNA methylation for HUVEC in the region 2121 to +59, the persistent DNA methylation for HuH7 cells and the intermediate methyl-
ation hepatocytes and HepG2 cells in this region. Black: HUVEC; white: hepatocytes; red: HepG2 cells; blue: HuH7 cells.
Figure 2 Comparison of basal t-PA expression in HUVEC and
human liver-derived cells. Antigen levels of t-PA in 24 h conditioned
medium of HUVEC, human primary hepatocytes, HepG2 or HuH7
cells was measured by ELISA (left) and t-PA mRNA levels by
qPCR (right). The results give mean values+ SEM (n ¼ 4), for a
representative experiment.
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and 16+ 3-fold more t-PA promoter DNA associated with
acetylated H4 histone, respectively, when compared with DNA
from non-treated cells (Figure 5).
3.4 Effect of histone acetyltransferase
inhibitors on t-PA expression by
endothelial cells
The increased acetylation at the t-PA promoter in EC treated with
HDAC inhibitors suggested the involvement of HAT. To determine
which HAT might have been involved we treated the EC with garcinol
(15 mM) and with anacardic acid (20 mM), inhibitors of both p300/
CBP and of PCAF as well as with curcumin (30 mM), an inhibitor of
p300/CBP but not of PCAF. Levels of t-PA mRNA were measured
in EC treated with these HAT inhibitors alone or in combination
with MS275 (3 mM). With garcinol and with anacardic acid, we
observed a reduction in basal and MS275-induced t-PA mRNA
levels, whereas curcumin had no effect (Figure 6).
4. Discussion
DNA methylation and histone modifications represent the major
epigenetic mechanisms regulating gene transcription. The results
Figure 5 Histone acetylation at the t-PA promoter of HUVEC
treated with HDAC inhibitors. HUVEC were treated for 6 h with tri-
chostatin (TSA, 3 mM) or MS275 (3 mM). Chromatin was isolated
and immunoprecipitated using antibodies specific for acetylated his-
tones H3 or histone H4. Associated t-PA promoter DNA was deter-
mined by quantitative PCR using primers for the region 21037 to
2846 with respect to the transcription initiation site of the t-PA
gene. The PCR results were normalized with respect to input
DNA. The results are shown as means+ SEM for four independent
experiments. *P, 0.005, Student’s t-test.
Figure 3 Effect of histone deacetylase inhibitors on t-PA
expression by HUVEC. Top: The cells were treated for 24 h with
different concentrations of the non-specific HDAC inhibitors buty-
rate or trichostatin (TSA) and t-PA antigen levels determined in
cell supernatants by ELISA. The results are shown as means+ SEM
for three independent experiments. Bottom: time response curves
for the effect of butyrate (3 mM) or trichostatin (1 mM) on t-PA
mRNA levels in HUVEC. The figure shows a representative exper-
iment of three independent experiments.
Figure 4 Effect of the class I-specific HDAC inhibitor MS275 on
t-PA expression by HUVEC. The cells were treated for 24 h with
different concentrations of the class I-specific HDAC inhibitor
MS275 and the effect on t-PA release (top) and mRNA levels
(bottom) determined by ELISA and quantitative PCR. The results
are shown as means+ SEM for three independent experiments.
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presented in this study imply that t-PA expression is under epigenetic
control and repressed by HDAC in non-stimulated EC. An analysis
of the CpG dinucleotide methylation state of the t-PA promoter
revealed a stretch from –121 to +59 in which the CpG dinucleotides
were unmethylated. In contrast, in human primary hepatocytes this
stretch was methylated and basal t-PA expression in these cells was
much lower than that in EC. Lowest levels of t-PA expression
occurred in HuH7 human hepatoma cells, in which CpGs in its pro-
moter region were more extensively methylated. These results are
in agreement with the concept that methylated CpG dinucleotides
at the proximal promoter are associated with gene inactivation
(Cedar, Nat Rev Genet 2008).22
We observed that HDAC inhibitors increase the expression of
t-PA by human EC. Our results confirm and extend a previous obser-
vation that the non-specific HDAC inhibitors trichostatin and butyrate
increase t-PA gene transcription in EC.13 In particular, our results
provide clear evidence that HDAC inhibitors have a direct effect
and modify the acetylation state of histones at the t-PA promoter.
Taken together, this suggests that in resting EC t-PA expression is
repressed by HDACs. MS275, an inhibitor directed only towards
class I HDAC, was the strongest inducer of t-PA mRNA with a half
maximum effect at 2 mM. This implies an important role for
HDAC1, HDAC2, or HDAC3. HDAC remove acetyl groups not
only from histones H3 or H4, but also may deacetylate other proteins
that have an effect on cell signalling.23 Our finding that acetylation of
histone H3 and histone H4 associated with the t-PA promoter was
increased in HUVEC after treatment with MS275 or trichostatin
suggests a direct effect of HDAC inhibitors on the t-PA promoter.
Treatment of EC with garcinol and anacardic acid, which are inhibitors
of the HATs P300/CBP and of PCAF, reduced basal and
MS275-induced expression of t-PA. In contrast, curcumin, an inhibitor
of P300/CBP but not of PCAF,24 had no effect on basal or
MS275-induced t-PA expression. This suggests a role for PCAF
rather than P300/CBP in regulation of t-PA expression.
Several regulatory elements have been identified within the t-PA
promoter. Among these are a TRE-element (TGACTCA) at position
2113 to 2106 of the t-PA promoter which is essential for basal t-PA
gene transcription.25 and, in EC, binds the AP-1 family members junD
and fra-2.26 Two CpG dinucleotides are found in the immediate vicin-
ity of this TRE, one is located immediately downstream, the other
located 8 bp upstream of this TRE. In EC these two CpG dinucleo-
tides are fully unmethylated, while in primary hepatocytes these are
.75% methylated (see Figure 1). It remains to be established to
what extent the difference in DNA methylation of these two CpG
dinucleotides are responsible for the 5- to 10-fold difference in
t-PA expression between HUVEC and primary hepatocytes. Other
regulatory elements in the proximal t-PA promoter are likewise
close to CpG dinucleotide residues. Thus a CTF/NF1 binding site
(TCAGCCTGGCCCGAA) at position 292 to 27726 contains a
CpG dinucleotide (position 281) that is unmethylated in EC and
human hepatocytes and 70% methylated in HuH7 cells (see
Figure 1). An AP2-like binding site (CCCCACCCCC) at position
+62 to +71 is located just downstream of a triplet of CpG dinucleo-
tides that are unmethylated in EC and partially methylated in hepa-
toma cells and HuH7 cells. This site is known to be required for
basal t-PA expression and to recruit the transcription factor
Sp1.25,27 Recruitment of co-repressor complexes to these methylated
CpG dinucleotide residues are likely to interfere with the binding of
AP-1 family members to the TRE element, which would explain the
lower expression of t-PA in hepatocytes and HUH7 cells. In contrast,
an Sp-1 binding site coincides with the CpG dinucleotide at position
2366, and was found to mediate the increased expression of t-PA
induced by quercitin in HUVEC.28 In HUVEC, this position is fully
methylated. Further work needs to be done to determine whether
Figure 6 Effect of histone acetyltransferase inhibitors on t-PA expression by endothelial cells. The cells were treated for 24 h with different com-
binations of the HDAC inhibitor MS275 (3 mM) and the histone acetyl transferase inhibitors garcinol (15 mM), anacardic acid (20 mM), and curcumin
(30 mM) as indicated below the figure. t-PA mRNA levels were determined by quantitative PCR. Note the inhibitory effect of garcinol and anacardic
acid on basal and MS275 induced t-PA mRNA and the lack of effect of curcumin. The results are shown as means+ SEM for three independent
experiments. Significance of differences: *P, 0.05; **P, 0.01; ns, non-significant.
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the close proximity of CpG dinucleotides with almost all known tran-
scription factor binding sites within the t-PA promoter is fortuitous or
has a functional relevance.
A limitation of the present study is the use of human EC in culture.
For primary early passage EC or hepatocytes, the methylation state of
the promoter is unlikely to be different from that in vivo. Other epige-
netic aspects that may impact on t-PA expression such as activity of
HDACs and HATs may be different from those in vivo. As HDAC
inhibitors are being developed for therapy of cancer and brain dis-
orders,29,30 it is likely that therapeutic use of inhibitors of DNA
methylation or of HDAC inhibitors has an impact on expression of
t-PA in vivo. Our finding, that hepatocytes cultured in vitro are
capable of t-PA production, raises the question as to what extent
these cells contribute to plasma t-PA concentrations.
In conclusion, regulation of t-PA in EC is under epigenetic control.
Methylation of the proximal t-PA promoter is associated with a
reduced expression of t-PA in hepatocytes and in HuH7 hepatoma
cells when compared with EC. Class I histone deacetylases repress
t-PA expression in EC, whereas the HAT PCAF has the opposite
effect. A better understanding of the epigenetic control mechanisms
modulating t-PA expression may help to establish to what extent epi-
genetic approaches that are being developed for therapies of cancer
or cardiovascular disease modify the vascular fibrinolytic system.
Further studies are needed to determine the tissue-specific aspects
of the epigenetic control of t-PA gene regulation.
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